Betta Pharmaceuticals Co Ltd
300558
Company Profile
Business description
Betta Pharmaceuticals Co Ltd is a pharmaceutical enterprise that focuses on the research and development of innovative medicines. The company's drug is used for various diseases such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Further, it offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. Geographically, the group operates in China.
Contact
No. 355, Xingzhong Road
Economic and Technological Development Zone
Yuhang District, Zhejiang Province
Hangzhou311100
CHNT: +86 57189265665
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
1,785
Stocks News & Analysis
stocks
ASX property share lifts guidance despite sector headwinds
Aussie property manager lifts earnings expectations despite interest rate uncertainty.
stocks
Why stocks sometimes fall for no obvious reason
How the private markets impact all equity investors.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,904.40 | 25.90 | 0.29% |
| CAC 40 | 8,173.11 | 85.15 | -1.03% |
| DAX 40 | 25,184.89 | 204.21 | -0.80% |
| Dow JONES (US) | 50,461.68 | 118.02 | -0.23% |
| FTSE 100 | 10,491.39 | 25.13 | 0.24% |
| HKSE | 25,416.92 | 182.53 | -0.71% |
| NASDAQ | 26,656.18 | 312.21 | 1.19% |
| Nikkei 225 | 65,816.62 | 820.53 | 1.26% |
| NZX 50 Index | 13,181.45 | 111.71 | 0.85% |
| S&P 500 | 7,519.12 | 45.65 | 0.61% |
| S&P/ASX 200 | 8,673.40 | 21.20 | 0.25% |
| SSE Composite Index | 4,122.21 | 23.17 | -0.56% |